

Friday, 12 August 2022

## **SECOND LETTER RECEIVED FROM CRESCENT CAPITAL PARTNERS**

Australian Clinical Labs Limited (ASX: ACL) (**ACL** or the **Company**) provides the market with a copy of a second letter which it has received from a shareholder, Crescent Capital Partners.

**– ENDS –**

This announcement was authorised for release to ASX by the Company Secretary of ACL.

For further information regarding this announcement, please contact:

### **Investors**

Eleanor Padman

Company Secretary

Email: [investors@clinicalabs.com.au](mailto:investors@clinicalabs.com.au)

Phone: +61 (0) 422 002 918

### **About Australian Clinical Labs**

ACL is a leading Australian private provider of pathology services. Our NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives.

12 August 2022

Melinda McGrath  
CEO  
Australian Clinical Labs Limited  
1868-1892 Dandenong Road  
Clayton VIC 3168

cc: Eleanor Padman (Company Secretary)

Dear Ms McGrath

**Sale of shareholding in Australian Clinical Labs Limited (ACL) (ASX:ACL)**

Attached is a media release from Crescent Capital Partners Management Pty Ltd in relation to its holding in ACL.

Yours sincerely

**CRESCENT CAPITAL PARTNERS MANAGEMENT PTY LTD**



---

Peter Lyon-Mercado  
Company Secretary

**Atts.**

12 August 2022


## **Partial sale of Crescent Entities and Crescent Co-investors' Stake in Australian Clinical Labs**

Further to its announcement dated 12 August 2022, Crescent Capital Partners Management Pty Ltd ("Crescent") today announced that the sale of 14.3% of issued shares outstanding in Australian Clinical Labs Limited (ASX:ACL) ("ACL" or the "Company") by Crescent Entities and Crescent Co-Investors<sup>1</sup>, has been completed.

The aggregate sale proceeds to be received by Crescent Entities and Crescent Co-Investors are A\$130.0m, representing A\$4.50 per ACL share.

Crescent Entities and Crescent Co-Investors retain in aggregate 30.1% of the issued shares outstanding.

For and on behalf of Crescent,



Peter Lyon-Mercado  
Company Secretary

---

<sup>1</sup> "Crescent Entities", "Crescent Co-Investors" and "Management Shareholders" have the meaning given to those terms in the prospectus lodged by ACL and ACL SaleCo Limited (ACN 648 177 646) with the Australian Securities and Investment Commission on 28 April 2021 and released to the ASX Market Announcements Platform on 14 May 2021.